[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549483":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":222,"collaborators":224,"id":227,"slug":11,"hasResults":228,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":11,"eligibilityCriteria":232,"healthyVolunteers":228,"sex":233,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":11,"studyType":239,"phases":240,"briefSummary":242,"conditions":243,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},{"fullName":5,"class":6},"Shanghai Jiaolian Drug Research and Development Co., Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"B013","EXPERIMENTAL",null,[13,14],"Drug: B013","Drug: Paclitaxel",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[14,19],"Drug: Placebo",[21,25,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.",[9],{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Paclitaxel","Paclitaxel: 80 mg\u002Fm\\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.",[9,16],{"type":22,"name":16,"description":30,"armGroupLabels":31,"otherNames":11},"Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.",[16],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Xiaohua Wu","CONTACT","0086-021-64175590","JJYIN555@163.com",[39,53,64,75,86,97,108,116,127,138,148,156,167,178,189,200,211],{"facility":40,"status":41,"city":42,"state":11,"zip":11,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Beijing Cancer Hospital","RECRUITING","Beijing","China",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51],{"name":52,"role":35,"phone":11,"phoneExt":11,"email":11},"Hong Zheng",{"facility":54,"status":41,"city":55,"state":11,"zip":11,"country":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"The First Affiliated Hospital of Bengbu Medical University","Bengbu",{"type":45,"coordinates":57},[58,59],117.36083,32.94083,{"lat":59,"lon":58},[62],{"name":63,"role":35,"phone":11,"phoneExt":11,"email":11},"Hongli Liu",{"facility":65,"status":41,"city":66,"state":11,"zip":11,"country":43,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"XiangYa Hospital CentralSouth University","Changsha",{"type":45,"coordinates":68},[69,70],112.97087,28.19874,{"lat":70,"lon":69},[73],{"name":74,"role":35,"phone":11,"phoneExt":11,"email":11},"Yu Zhang",{"facility":76,"status":41,"city":77,"state":11,"zip":11,"country":43,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Fujian Cancer Hospital","Fuzhou",{"type":45,"coordinates":79},[80,81],119.30611,26.06139,{"lat":81,"lon":80},[84],{"name":85,"role":35,"phone":11,"phoneExt":11,"email":11},"Rong Xie",{"facility":87,"status":41,"city":88,"state":11,"zip":11,"country":43,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Sun Yat-sen Memorial Hospital, Sun Yat-sen University","Guangzhou",{"type":45,"coordinates":90},[91,92],113.25,23.11667,{"lat":92,"lon":91},[95],{"name":96,"role":35,"phone":11,"phoneExt":11,"email":11},"Qunxian Rao",{"facility":98,"status":41,"city":99,"state":11,"zip":11,"country":43,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Cancer Hospital of Shandong First Medical University","Jinan",{"type":45,"coordinates":101},[102,103],116.99722,36.66833,{"lat":103,"lon":102},[106],{"name":107,"role":35,"phone":11,"phoneExt":11,"email":11},"Liang Chen",{"facility":109,"status":41,"city":99,"state":11,"zip":11,"country":43,"cosmosGeoPoint":110,"geoPoint":112,"contacts":113},"Qilu Hospital of Shandong University",{"type":45,"coordinates":111},[102,103],{"lat":103,"lon":102},[114],{"name":115,"role":35,"phone":11,"phoneExt":11,"email":11},"Kun Song",{"facility":117,"status":41,"city":118,"state":11,"zip":11,"country":43,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Yunnan Cancer Hospital","Kunming",{"type":45,"coordinates":120},[121,122],102.71833,25.03889,{"lat":122,"lon":121},[125],{"name":126,"role":35,"phone":11,"phoneExt":11,"email":11},"Hongying Yang",{"facility":128,"status":41,"city":129,"state":11,"zip":11,"country":43,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Guangxi Medical University Cancer Hospital","Nanning",{"type":45,"coordinates":131},[132,133],108.31667,22.81667,{"lat":133,"lon":132},[136],{"name":137,"role":35,"phone":11,"phoneExt":11,"email":11},"He Wang",{"facility":139,"status":41,"city":140,"state":11,"zip":11,"country":43,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Fudan University Shanghai Cancer center","Shanghai",{"type":45,"coordinates":142},[143,144],121.45806,31.22222,{"lat":144,"lon":143},[147],{"name":34,"role":35,"phone":11,"phoneExt":11,"email":11},{"facility":149,"status":41,"city":140,"state":11,"zip":11,"country":43,"cosmosGeoPoint":150,"geoPoint":152,"contacts":153},"The Obstetrics & Gynecology Hospital of Fudan University",{"type":45,"coordinates":151},[143,144],{"lat":144,"lon":143},[154],{"name":155,"role":35,"phone":11,"phoneExt":11,"email":11},"Xin Lu",{"facility":157,"status":41,"city":158,"state":11,"zip":11,"country":43,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"The Second Hospital of Hebei Medical University","Shijiazhuang",{"type":45,"coordinates":160},[161,162],114.47861,38.04139,{"lat":162,"lon":161},[165],{"name":166,"role":35,"phone":11,"phoneExt":11,"email":11},"Xianghua Huang",{"facility":168,"status":41,"city":169,"state":11,"zip":11,"country":43,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan",{"type":45,"coordinates":171},[172,173],114.26667,30.58333,{"lat":173,"lon":172},[176],{"name":177,"role":35,"phone":11,"phoneExt":11,"email":11},"Guiling Li",{"facility":179,"status":41,"city":180,"state":11,"zip":11,"country":43,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Shananxi Provincial Cancer Hospital","Xi'an",{"type":45,"coordinates":182},[183,184],108.92861,34.25833,{"lat":184,"lon":183},[187],{"name":188,"role":35,"phone":11,"phoneExt":11,"email":11},"Guoqing Wang",{"facility":190,"status":41,"city":191,"state":11,"zip":11,"country":43,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"The First Affiliated Hospital of Xiamen University","Xiamen",{"type":45,"coordinates":193},[194,195],118.08187,24.47979,{"lat":195,"lon":194},[198],{"name":199,"role":35,"phone":11,"phoneExt":11,"email":11},"Jianfa Lan",{"facility":201,"status":41,"city":202,"state":11,"zip":11,"country":43,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Yibin city second people's Hospital","Yibin",{"type":45,"coordinates":204},[205,206],104.63994,28.7593,{"lat":206,"lon":205},[209],{"name":210,"role":35,"phone":11,"phoneExt":11,"email":11},"Kaijian Lei",{"facility":212,"status":41,"city":213,"state":11,"zip":11,"country":43,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Henan Cancer Hospital","Zhengzhou",{"type":45,"coordinates":215},[216,217],113.64861,34.75778,{"lat":217,"lon":216},[220],{"name":221,"role":35,"phone":11,"phoneExt":11,"email":11},"Yanlin Luo",{"type":223,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[225],{"name":226,"class":6},"Shanghai Pharmaceuticals Holding Co., Ltd","100549483",false,"NCT06434610","A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.","Inclusion Criteria:\n\n1. Subjects who voluntarily participate in this study and sign informed consent form;\n2. Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum resistance recurrence;\n3. ECOG performance status of 0 or 1；\n4. Expected survival \\> 12 weeks;\n5. The subject has at least one measurable lesion;\n6. Normal function of major organs;\n7. The fertile subjects agree to use reliable contraception from signing the informed consent to at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Subjects who have received prescribed treatment previously;\n2. Subjects who are still using anti-tumor traditional Chinese patent medicines at the time of signing informed consent;\n3. Subjects with known central nervous system metastasis and multiple bone metastasis;\n4. Subjects who had clinical symptoms of pleural effusion, pericardial effusion or ascites before randomization and needed puncture drainage, or had received puncture drainage within the previous 2 weeks;\n5. Have a history of other malignant tumors within 5 years before signing the informed consent;\n6. Subjects with prescribed cardiovascular diseases;\n7. Subjects with infections requiring intravenous antibiotic infusion within 2 weeks prior to randomization;\n8. Had severe lung disease before randomization;\n9. Before randomization, the peripheral nerve toxicity of previous anti-tumor treatment was \\> grade 2, and other reversible toxicity was \\> grade 1;\n10. Subjects who had undergone surgery within 28 days prior to randomization and did not recover from adverse effects of surgery;\n11. Subjects who participated in clinical trials within 30 days prior to randomization and received other unmarketed investigational drugs;\n12. Subjects who are known to be allergic to any component of B013 or paclitaxel.\n13. Subjects with a known history of substance abuse, alcohol or drug use; Subjects with a known history of neurological or psychiatric disorders;\n14. Female subjects who are pregnant or breastfeeding;\n15. Other situations determined by the researchers and\u002For sponsors as unsuitable for participation in this trial.","FEMALE","18 Years","75 Years",{"count":237,"type":238},90,"ESTIMATED","INTERVENTIONAL",[241],"PHASE2","To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.",[244],"Platinum-resistant Recurrent Ovarian Cancer","2026-04-29",{"date":247,"type":248},"2026-05-05","ACTUAL",{"date":250,"type":248},"2024-07-11",{"date":252,"type":238},"2026-12-31",{"name":5,"class":6},17]